Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study
Sponsor: Coordinación de Investigación en Salud, Mexico
Listed as NCT03006419, this PHASE4 trial focuses on Kidney Transplant Rejection and Kidney Transplant; Complications and remains completed. Sponsored by Coordinación de Investigación en Salud, Mexico, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Coordinación de Investigación en Salud, Mexico
For direct contact, visit the study record on ClinicalTrials.gov .